BG98194A - Фибриногенни рецепторни антагонисти - Google Patents

Фибриногенни рецепторни антагонисти Download PDF

Info

Publication number
BG98194A
BG98194A BG98194A BG9819493A BG98194A BG 98194 A BG98194 A BG 98194A BG 98194 A BG98194 A BG 98194A BG 9819493 A BG9819493 A BG 9819493A BG 98194 A BG98194 A BG 98194A
Authority
BG
Bulgaria
Prior art keywords
agent
mammal
pharmaceutically acceptable
administered
inhibiting
Prior art date
Application number
BG98194A
Other languages
Bulgarian (bg)
English (en)
Inventor
Mark Duggan
George Hartman
Melissa Egbertson
Nathan Ihle
Laura Turchi
Wiliam Hoffman
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG98194A publication Critical patent/BG98194A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Materials For Medical Uses (AREA)
BG98194A 1991-05-07 1993-11-02 Фибриногенни рецепторни антагонисти BG98194A (bg)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69689391A 1991-05-07 1991-05-07
US72035791A 1991-06-25 1991-06-25
US87126292A 1992-04-23 1992-04-23
PCT/US1992/003463 WO1992019595A1 (en) 1991-05-07 1992-04-27 Fibrinogen receptor antagonists

Publications (1)

Publication Number Publication Date
BG98194A true BG98194A (bg) 1994-09-30

Family

ID=27418643

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98194A BG98194A (bg) 1991-05-07 1993-11-02 Фибриногенни рецепторни антагонисти

Country Status (20)

Country Link
US (2) US5281585A (de)
EP (1) EP0512831B1 (de)
JP (1) JP2531562B2 (de)
KR (1) KR920021531A (de)
CN (1) CN1067883A (de)
AT (1) ATE184874T1 (de)
AU (1) AU647618B2 (de)
BG (1) BG98194A (de)
CA (1) CA2068064C (de)
DE (1) DE69230013T2 (de)
ES (1) ES2137175T3 (de)
FI (1) FI934894L (de)
HU (1) HUT68769A (de)
IE (1) IE921463A1 (de)
IL (1) IL101779A0 (de)
MX (1) MXPA92002103A (de)
NO (1) NO933999L (de)
NZ (1) NZ242609A (de)
WO (1) WO1992019595A1 (de)
YU (1) YU47992A (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
WO1993018058A1 (en) * 1992-03-06 1993-09-16 G.D. Searle & Co. Peptides mimics useful as platelet aggregation inhibitors
CA2150550A1 (en) * 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
DE4308034A1 (de) * 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
EP0690847A1 (de) * 1993-03-29 1996-01-10 Zeneca Limited Heterozyklische derivate als plätchenaggregationsinhibitoren
DK0691959T3 (da) * 1993-03-29 1999-04-26 Zeneca Ltd Heterocykliske derivater som blodpladeaggregations-inhibitorer
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
DE69429328T2 (de) * 1993-09-22 2002-06-13 Fujisawa Pharmaceutical Co., Ltd. N-(3-piperidinylcarbonyl)-b-alanin derivate als paf-antagonisten
WO1995011228A1 (en) * 1993-10-19 1995-04-27 Sumitomo Pharmaceuticals Co., Ltd. 2,3-diaminopropionic acid derivative
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
CA2174838A1 (en) * 1993-11-24 1995-06-01 John Wityak Novel isoxazoline and isoxazole fibrinogen receptor antagonists
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69530683T2 (de) * 1994-03-11 2004-03-25 Pharmacopeia, Inc. Sulfonamid derivate und deren verwendung
AU7836594A (en) * 1994-03-14 1995-10-03 Merck & Co., Inc. Pyridyl ethylation of lactam derivatives
US5665882A (en) * 1994-03-14 1997-09-09 Merck & Co., Inc. Pyridyl ethylation of lactams
RU2156763C2 (ru) * 1994-07-15 2000-09-27 Мейдзи Сейка Кабусики Кайся Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и способ лечения или профилактики тромботических заболеваний
US5451578A (en) * 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
US5525617A (en) * 1994-08-24 1996-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5686607A (en) * 1994-09-16 1997-11-11 Merck & Co., Inc. Pyridyl ethylation of lactam derivatives
US5494921A (en) * 1994-09-16 1996-02-27 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1996013497A1 (en) * 1994-11-01 1996-05-09 Terumo Kabushiki Kaisha Tetrahydroisoquinoline derivative and medicinal preparation containing the same
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
US5674894A (en) * 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US5852045A (en) * 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0866705A4 (de) * 1995-10-19 1999-03-03 Merck & Co Inc Fibrinogenrezeptorantagonisten
EP0880511A4 (de) * 1996-01-16 1999-06-16 Merck & Co Inc Integrin-rezeptor-antagonisten
US5952306A (en) * 1996-01-16 1999-09-14 Merck & Co., Inc. Integrin receptor antagonists
KR19990087694A (ko) * 1996-03-13 1999-12-27 후지야마 아키라 피브리노겐 수용체 길항제로서의 N-[(R)-１-{３-(４-피페리딜)프로피오닐-３-피페리딜카보닐]-２(S)-아세틸아미노-β-알라닌
GB2312895A (en) * 1996-05-10 1997-11-12 Merck & Co Inc Fibrinogen receptor antagonists
US5889023A (en) * 1996-05-10 1999-03-30 Merck & Co., Inc. Fibrinogen receptor antagonist
US5961483A (en) * 1996-06-19 1999-10-05 Sage; Burton H. Iontophoretic delivery of cell adhesion inhibitors
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
US6211184B1 (en) * 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
CA2265827A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5978698A (en) * 1996-10-08 1999-11-02 Merck & Co., Inc. Angioplasty procedure using nonionic contrast media
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
US5952341A (en) * 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US5981584A (en) * 1997-02-06 1999-11-09 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
AU747531B2 (en) 1997-04-14 2002-05-16 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US6133256A (en) * 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
EP0977772A1 (de) 1997-04-14 2000-02-09 Cor Therapeutics, Inc. Selektive faktor xa-inhibitoren
US6294549B1 (en) 1997-07-23 2001-09-25 Merck & Co., Inc. Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
AU742853B2 (en) * 1997-07-31 2002-01-17 Ube Industries, Ltd. N-acylamino acid amide compounds and intermediates for preparation thereof
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
GB2328871A (en) * 1997-09-05 1999-03-10 Merck & Co Inc Compositions for inhibiting platelet aggregation
GB2328873A (en) * 1997-09-08 1999-03-10 Merck & Co Inc The use of [3(R)-[2-(piperidin-4-yl)ethyl]-2-piperidone-1]acetyl-3(R)-methyl-ß-alanine for inhibiting blood platelet aggregation
JP2001524481A (ja) * 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
US6211191B1 (en) 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6623981B2 (en) * 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
WO2000029406A2 (en) 1998-11-18 2000-05-25 Du Pont Pharmaceuticals Company Novel isoxazoline fibrinogen receptor antagonists
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
SK288186B6 (sk) * 1999-05-07 2014-05-06 Encysive Pharmaceuticals, Inc. Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP1229910A4 (de) 1999-10-04 2003-10-01 Merck & Co Inc Integrinrezeptorantagonisten
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
AR030817A1 (es) 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003007949A1 (en) * 2001-07-18 2003-01-30 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
WO2004101523A1 (en) * 2003-05-17 2004-11-25 Korea Research Institute Of Bioscience And Biotechnology Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
US20070087061A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Method and composition for creating and/or activating a platelet-rich gel by contact with a porous particulate material, for use in wound care, tissue adhesion, or as a matrix for delivery of therapeutic components
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CA2769408C (en) * 2009-07-30 2017-09-05 Laboratorios Salvat, S.A. Apaf-1 inhibitor compounds
EP3026432A3 (de) 2010-12-27 2016-07-27 Brown University Verfahren zur vorhersage der patientenreaktion auf eine behandlung mit biglycan
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
US10792771B2 (en) 2017-09-12 2020-10-06 Raytheon Technologies Corporation Method of making integrally bladed rotor
US10605101B2 (en) 2017-09-12 2020-03-31 United Technologies Corporation Process of making integrally bladed rotor
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
FR2334358A1 (fr) * 1975-12-12 1977-07-08 Sogeras Nouveaux medicaments derives de l'indole
US4064125A (en) * 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
EP0021592B1 (de) * 1979-05-23 1983-09-28 BEECHAM - WUELFING GmbH & Co. KG Benzolsulfonamid-Derivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Medikamente
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
NZ234264A (en) * 1989-06-29 1993-05-26 Warner Lambert Co N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP2531562B2 (ja) 1996-09-04
WO1992019595A1 (en) 1992-11-12
HUT68769A (en) 1995-07-28
ATE184874T1 (de) 1999-10-15
NZ242609A (en) 1995-04-27
FI934894A7 (fi) 1993-11-05
CA2068064A1 (en) 1992-11-08
FI934894A0 (fi) 1993-11-05
DE69230013T2 (de) 2000-04-27
AU1611192A (en) 1992-11-12
HU9303145D0 (en) 1994-01-28
CA2068064C (en) 2001-01-02
US5455243A (en) 1995-10-03
ES2137175T3 (es) 1999-12-16
EP0512831A1 (de) 1992-11-11
KR920021531A (ko) 1992-12-18
AU647618B2 (en) 1994-03-24
MXPA92002103A (es) 2005-08-25
JPH069525A (ja) 1994-01-18
FI934894L (fi) 1993-11-05
NO933999D0 (no) 1993-11-05
IE921463A1 (en) 1992-11-18
NO933999L (no) 1993-11-05
CN1067883A (zh) 1993-01-13
YU47992A (sh) 1995-03-27
DE69230013D1 (de) 1999-10-28
EP0512831B1 (de) 1999-09-22
IL101779A0 (en) 1992-12-30
US5281585A (en) 1994-01-25

Similar Documents

Publication Publication Date Title
EP0512831B1 (de) Fibrinogen-Rezeptor-Antagonisten
DE69224552T2 (de) Fibrinogen-Rezeptor-Antagonisten
EP0478362B1 (de) Fibrinogen-Rezeptor-Antagonisten
DE69207351T2 (de) Fibrinogen-Rezeptor-Antagoniste
US5264420A (en) Fibrinogen receptor antagonists
CZ359997A3 (cs) Pětičlenné heterocyklické sloučeniny jako inhibitory adheze leukocytů a antagonisté VLA-4 a farmaceutický přípravek, který je obsahuje
PL188042B1 (pl) Nowe pochodne dioksoimidazolidyny, środek farmaceutyczny i zastosowanie pochodnych dioksoimidazolidyny
CZ134296A3 (en) Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
JPH10503204A (ja) トロンビン阻害剤
JPH0517498A (ja) フイブリノーゲンレセプター拮抗剤
JPH10511359A (ja) フィブリノゲン受容体拮抗物質
JPH07501057A (ja) フィブリノーゲン・アンタゴニスト用ｃ８−環状ペプチド模倣体
RU2240326C2 (ru) Новые пятичленные гетероциклы, их получение, их применение и содержащие их фармацевтические препараты
KR100328287B1 (ko) 항혈전제화합물로서의니페코트산유도체
JPH10511357A (ja) フィブリノゲン受容体拮抗物質
JPH02300199A (ja) レトロウイルスプロテアーゼ阻害剤
DE19850131A1 (de) Chromenon- und Chromanonderivate
SK7452001A3 (en) Vitronectin receptor antagonist
JPH08508501A (ja) フィブリノーゲンレセプターアンタゴニスト
JPH10511356A (ja) フィブリノゲン受容体拮抗物質
US5753667A (en) 1-oxo-2- (phenylsulphonylamino) pentylpiperidine derivatives, their preparation and their therapeutic application
CZ20032429A3 (cs) Imidazolidinové deriváty, způsob jejich přípravy a jejich použití jako protizánětlivých prostředků
LT3284B (en) Fibrinogen receptor antagonists
JP2002506039A (ja) フィブリノーゲン受容体アンタゴニスト
LV10425B (en) Fibrinogen receptor antagonists